Stereotactic body radiation therapy for pleural mesothelioma: which goal, which patients
We read with interest the article by Shin et al. [1], recently published in Radiotherapy& Oncology. We commend the authors for reporting the results of the largest cohort to date investigating Stereotactic Body Radiation Therapy (SBRT) in pleural mesothelioma (PM). We fully agree with their conclusions that an adequate local control in this setting without significant toxicity can be achieved with non-ablative total doses, keeping the dose per fraction relatively high. (Source: Radiotherapy and Oncology)
Source: Radiotherapy and Oncology - February 8, 2024 Category: Radiology Authors: Giovanni L. Ceresoli, Paolo Ghirardelli, Vittorio Vavassori Tags: Letter to the Editor Source Type: research
Elaborate cooperation of poly(rC)-binding proteins 1/2 and glutathione in ferroptosis induced by plasma-activated Ringer's lactate
In conclusion, PAL can selectively sensitize MM cells to ferroptosis by remodeling cytoplasmic iron homeostasis, where glutathione and PCBPs play distinct roles, resulting in lethal ferritinophagy and mitochondrial dysfunction. Our findings indicate the clinical application of PAL as a ferroptosis-inducer and the potential of PCBPs as novel targets in cancer therapeutics.PMID:38325565 | DOI:10.1016/j.freeradbiomed.2024.02.001 (Source: Free Radical Biology and Medicine)
Source: Free Radical Biology and Medicine - February 7, 2024 Category: Biology Authors: Li Jiang Hao Zheng Moe Ishida Qinying Lyu Shinya Akatsuka Yashiro Motooka Kotaro Sato Yoshitaka Sekido Kae Nakamura Hiromasa Tanaka Kenji Ishikawa Hiroaki Kajiyama Masaaki Mizuno Masaru Hori Shinya Toyokuni Source Type: research
Pediatric, Adolescent and Young Adult (AYA) Peritoneal and Pleural Mesothelioma: A National Cancer Database Review
Malignant peritoneal and pleural mesothelioma are rare in young patients, with a paucity of data regarding clinical characteristics and outcomes. We aimed to describe the clinical characteristics, treatment strategies, and outcomes for pediatric and adolescent/young adult (AYA) patients. (Source: Journal of Pediatric Surgery)
Source: Journal of Pediatric Surgery - February 6, 2024 Category: Surgery Authors: Colleen P. Nofi, Bailey K. Roberts, Barrie S. Rich, Richard D. Glick Source Type: research
PET-CT-guided versus CT-guided biopsy in suspected malignant pleural thickening: a randomised trial
Extract
Pleural malignancy represents either metastases from another primary site (often lung, breast or ovarian) or primary pleural malignancy from pleural mesothelioma [1]. Pleural malignancy, especially pleural mesothelioma, can be challenging to diagnose due to the patchy distribution of heterogenous tumour across the pleural surface [2]. Pleural biopsy via image guidance or thoracoscopy has a false negative rate of 10–25% [3, 4]. For those with a non-diagnostic first pleural biopsy, but ongoing clinical or radiological suspicion of malignancy, the optimal approach is unclear. (Source: European Respiratory Journal)
Source: European Respiratory Journal - February 1, 2024 Category: Respiratory Medicine Authors: de Fonseka, D., Arnold, D. T., Smartt, H. J. M., Culliford, L., Stadon, L., Tucker, E., Morley, A., Zahan-Evans, N., Bibby, A. C., Lynch, G., Mishra, E., Khan, S., Haris, M., Steer, H., Lewis, L., Ionescu, A., Harvey, J., Blyth, K., Rahman, N. M., Edey, A Tags: Lung cancer Original Articles: Imaging and pleural disease Source Type: research
TARGETing the utility of CT-guided pleural biopsy facilitated by PET-CT imaging
Extract
Malignancy is the most common cause of exudative pleural effusions [1, 2]. About 40% of patients with lung cancer, which is the predominant aetiology of malignant pleurisy [3], develop pleural effusions during the course of their illness [4]. In addition, approximately 90% of pleural mesotheliomas exhibit a unilateral pleural effusion on computed tomography (CT) [5]. Pleural fluid cytological examination remains the gold standard for diagnosing malignant pleural effusion (MPE). However, its overall sensitivity is roughly 50%, and remains particularly low in squamous cell lung cancer (14–24%) and mesothelioma ...
Source: European Respiratory Journal - February 1, 2024 Category: Respiratory Medicine Authors: Bodtger, U., Porcel, J. M. Tags: Editorials Source Type: research
